01.2022
Ventac Partners portfolio company Orbit Genomics announced it has received $3 million in funding to launch its first product, OrbiSeq™ – L, a lung cancer diagnostic test with lead investors NHH Ventures and New Horizon Health Ltd (6606-HK). The company is raising an additional $1 million to complete the $4 million round. It also entered into an exclusive licensing agreement with New Horizon Health Ltd to market Orbit Genomics' products in Asia.” More information on this transaction is available at this link.
12.2021
APIM Therapeutics announced today that a Phase II Investigator Initiated Study (IIS) of ATX-101 will begin enrolling patients with sarcoma at Columbia University Irving Medical Center. The clinical study will investigate ATX-101 as single agent therapy for patients with leiomyosarcoma and liposarcoma who have received at least one prior treatment. For a copy of the corresponding press release, please follow this link.
11.2021
APIM Therapeutics announced today that the first patient has been treated with ATX-101 in the company's phase I/II ovarian cancer study. The clinical study investigates ATX-101 in combination with platinum-based chemotherapy and comprises two parts: Part 1 is a safety part with dose limiting toxicity as primary endpoint; Part 2 is an efficacy part with progression free survival as primary endpoint. For a copy of the corresponding press release, please follow this link.